These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38619025)

  • 1. Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
    Destremau M; Chaussade H; Hemar V; Beguet M; Bellecave P; Blanchard E; Barret A; Laboure G; Vasco-Moynet C; Lacassin F; Morisse E; Aguilar C; Lafarge X; Lafon ME; Bonnet F; Issa N; Camou F
    J Med Virol; 2024 Apr; 96(4):e29603. PubMed ID: 38619025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.
    Camou F; Tinevez C; Beguet-Yachine M; Bellecave P; Ratiarison D; Tumiotto C; Lafarge X; Guisset O; Mourissoux G; Lafon ME; Bonnet F; Issa N
    J Med Virol; 2021 Sep; 93(9):5594-5598. PubMed ID: 33942327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
    Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
    Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
    Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
    Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity.
    Nomoto H; Kutsuna S; Okuma K; Kuramitsu M; Tezuka K; Ikebe E; Saito S; Kinoshita N; Terada M; Endo M; Suzuki T; Miyazato Y; Nakamoto T; Inada M; Hamaguchi I; Ohmagari N
    J Infect Chemother; 2021 Apr; 27(4):653-655. PubMed ID: 33487533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.
    Jeyaraman P; Agrawal N; Bhargava R; Bansal D; Ahmed R; Bhurani D; Bansal S; Rastogi N; Borah P; Naithani R;
    Transfus Apher Sci; 2021 Jun; 60(3):103075. PubMed ID: 33574010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.
    Senefeld JW; Franchini M; Mengoli C; Cruciani M; Zani M; Gorman EK; Focosi D; Casadevall A; Joyner MJ
    JAMA Netw Open; 2023 Jan; 6(1):e2250647. PubMed ID: 36633846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.
    Rajendran K; Krishnasamy N; Rangarajan J; Rathinam J; Natarajan M; Ramachandran A
    J Med Virol; 2020 Sep; 92(9):1475-1483. PubMed ID: 32356910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
    Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
    Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C; Chai KL; Piechotta V; Valk SJ; Kimber C; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Jindal A; Cryns N; Estcourt LJ; Kreuzberger N; Skoetz N
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013600. PubMed ID: 36734509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases.
    Ljungquist O; Lundgren M; Iliachenko E; Månsson F; Böttiger B; Landin-Olsson M; Wikén C; Rosendal E; Överby AK; Wigren BJ; Forsell MNE; Kjeldsen-Kragh J; Rasmussen M; Kahn F; Holm K
    Infect Dis (Lond); 2022 Apr; 54(4):283-291. PubMed ID: 34878955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
    Guo W; Zheng Y; Feng S
    Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study.
    Nontawong N; Siripongboonsitti T; Tawinprai K; Boonpratoom M; Krailassiri N; Boonkhum C; Soonklang K; Poovorawan Y; Mahanonda N
    Ann Clin Microbiol Antimicrob; 2022 Nov; 21(1):51. PubMed ID: 36403020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
    Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
    Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Convalescent Plasma Therapy in COVID-19 Patients with Hematological Malignancies: A Systematic Review.
    Shibeeb S; Ajaj I; Al-Jighefee H; Abdallah AM
    Hematol Rep; 2022 Dec; 14(4):377-388. PubMed ID: 36547236
    [No Abstract]   [Full Text] [Related]  

  • 20. Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B-cell depleted patients with persistent COVID-19.
    Inbar T; Dann EJ; Kerner O; Stern A
    Transfusion; 2024 Mar; 64(3):443-448. PubMed ID: 38327238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.